Medicare Enrolled
Dr. Dan La, MD
Rheumatology · Tujunga, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. La from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. La?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. La
Dr. Dan La is a rheumatology specialist in Tujunga, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. La performed 23,661 Medicare services across 1,686 unique beneficiaries.
Between the years covered by Open Payments, Dr. La received a total of $59,789 from 55 pharmaceutical and/or device companies across 1734 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. La is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 16% volume in CA
$59,789 industry payments
Medicare Practice Summary
Medicare Utilization ↗23,661
Medicare services
Top 16% in CA for rheumatology
1,686
Unique beneficiaries
$41
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,245 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
12,450 | $34 | $110 |
| Denosumab injection (Prolia/Xgeva) | 6,120 | $18 | $50 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
2,053 | $107 | $300 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
447 | $67 | $150 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
420 | $1 | $40 |
| Ultrasound-guided large joint aspiration or injection This procedure uses ultrasound imaging to guide the removal of fluid from or the injection of medication into a large joint. |
377 | $89 | $300 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
364 | $26 | $300 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
312 | $102 | $150 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
284 | $123 | $600 |
| Viscosupplementation injection for joint An injection of hyaluronic acid or a derivative into a joint to provide lubrication and cushioning. |
238 | $59 | $285 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
146 | $68 | $120 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
91 | $141 | $500 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
86 | $77 | $200 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
72 | $149 | $300 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
55 | $148 | $400 |
| Methylprednisolone acetate injection, 20 mg A 20 mg injection of methylprednisolone acetate, a corticosteroid medication. This code specifies the drug and dosage administered. |
41 | $5 | $80 |
| Injection, methylprednisolone acetate, 40 mg | 32 | $6 | $160 |
| Ultrasound guidance for needle placement Use of ultrasound imaging to guide the precise placement of a needle during a medical procedure. |
24 | $53 | $300 |
| Ultrasound-guided joint aspiration or injection Removal of fluid from or injection into a medium-sized joint using ultrasound guidance to ensure accurate placement. |
17 | $81 | $200 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
17 | $6 | $50 |
| Tendon or ligament injection A procedure involving the injection of medication into a tendon or ligament. |
15 | $52 | $250 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
53.8% high complexity
34.3% medium
11.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$59,789
Total received (2018-2024)
Avg $8,541/year across 7 years
Top 10% in CA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
55
Companies
1,734
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$33,059 (55.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$25,374 (42.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,355 (2.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$5,960
2023
$4,424
2022
$5,343
2021
$4,408
2020
$6,563
2019
$18,401
2018
$14,691
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$1,318
Janssen Scientific Affairs, LLC
$1,007
PFIZER INC.
$496
Janssen Biotech, Inc.
$440
Novartis Pharmaceuticals Corporation
$432
ABBVIE INC.
$400
GlaxoSmithKline, LLC.
$361
Aurinia Pharma U.S., Inc.
$197
UCB, Inc.
$180
Fresenius Kabi USA, LLC
$151
E.R. Squibb & Sons, L.L.C.
$127
Kiniksa Pharmaceuticals International, plc
$126
Alexion Pharmaceuticals, Inc.
$114
Radius Health, Inc.
$98
Mallinckrodt Hospital Products Inc.
$76
AstraZeneca Pharmaceuticals LP
$75
ANI Pharmaceuticals, Inc.
$65
SCILEX PHARMACEUTICALS INC.
$55
Genentech USA, Inc.
$38
SOBI, INC
$32
United Therapeutics Corporation
$26
DePuy Synthes Sales Inc.
$25
Octapharma USA, Inc.
$23
DJO, LLC
$18
SHORLA ONCOLOGY INC.
$17
Bioventus LLC
$17
Teva Pharmaceuticals USA, Inc.
$16
Boehringer Ingelheim Pharmaceuticals, Inc.
$15
Azurity Pharmaceuticals, Inc.
$14
Top 3 companies account for 47.3% of 2024 payments
All-time payments by company (2018-2024) ›
AbbVie, Inc.
$19,919
Amgen Inc.
$8,328
Horizon Therapeutics plc
$4,217
AbbVie Inc.
$2,923
Janssen Biotech, Inc.
$2,221
PFIZER INC.
$2,186
Novartis Pharmaceuticals Corporation
$2,120
Celgene Corporation
$1,849
ABBVIE INC.
$1,803
GlaxoSmithKline, LLC.
$1,520
E.R. Squibb & Sons, L.L.C.
$1,453
Lilly USA, LLC
$1,057
Janssen Scientific Affairs, LLC
$1,007
Radius Health, Inc.
$959
GENZYME CORPORATION
$916
UCB, Inc.
$891
AstraZeneca Pharmaceuticals LP
$845
Alexion Pharmaceuticals, Inc.
$692
Aurinia Pharma U.S., Inc.
$665
Mallinckrodt Hospital Products Inc.
$543
Fresenius Kabi USA, LLC
$378
Horizon Pharma plc
$359
MEDEXUS PHARMA, INC.
$315
Genentech USA, Inc.
$269
MEDAC PHARMA, INC.
$217
Bayer Healthcare Pharmaceuticals Inc.
$200
Bayer HealthCare Pharmaceuticals Inc.
$183
DePuy Synthes Sales Inc.
$181
Mallinckrodt LLC
$171
Kowa Pharmaceuticals America, Inc.
$155
Takeda Pharmaceuticals U.S.A., Inc.
$135
Actelion Pharmaceuticals US, Inc.
$128
Kiniksa Pharmaceuticals International, plc
$126
Hikma Pharmaceuticals USA
$123
Bioventus LLC
$80
SOBI, INC
$77
Boehringer Ingelheim Pharmaceuticals, Inc.
$76
ANI Pharmaceuticals, Inc.
$65
SCILEX PHARMACEUTICALS INC.
$55
West-Ward Pharmaceuticals
$49
Sobi, Inc
$38
Flexion Therapeutics, Inc.
$29
United Therapeutics Corporation
$26
Kiniksa Pharmaceuticals, Ltd.
$25
ARGENX US, INC.
$25
SANOFI-AVENTIS U.S. LLC
$24
Zimmer Biomet Holdings, Inc.
$24
Ironwood Pharmaceuticals, Inc
$23
Octapharma USA, Inc.
$23
DJO, LLC
$18
SHORLA ONCOLOGY INC.
$17
Teva Pharmaceuticals USA, Inc.
$16
Azurity Pharmaceuticals, Inc.
$14
Merck Sharp & Dohme Corporation
$14
Antares Pharma, Inc.
$13
Top 3 companies account for 54.3% of all-time payments
Associated products mentioned in payments ›
ACTHAR · Actemra · Adempas · Arcalyst · BENLYSTA · Bimzelx · Briviact · COSENTYX · CYLTEZO · Cimzia · DONJOY · DUROLANE · DUZALLO · EVENITY · EVUSHELD · Enbrel · FORTEO · Gel-One Cross-linked Hyaluronate · HUMIRA · Humira · IDACIO · ILARIS · INFLECTRA · JYLAMVO · KEVZARA · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · LYRICA · Livalo · MONOVISC · Mitigare · Nayzilam · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · OLUMIANT · OPSUMIT · OPSUMIT MACITENTAN · ORENCIA · ORTHOVISC · Otezla · Otrexup · PANZYGA · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SEGLENTIS · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · Seglentis · Strensiq · Supartz · Supartz FX Sodium Hyaluronate · TALTZ · TAVNEOS · TREMFYA · TYVASO · Tavneos · Truxima · Tyenne · Tymlos · ULTOMIRIS · UPTRAVI · Uloric · Ultomiris · VIMOVO · VYVGART · XELJANZ · ZEPOSIA · ZTLido · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (55%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 10% for rheumatology in CA.
Geographic Context
Rheumatologists within 10 mi
153
Per 100K population
1.6
County median income
$87,760
Nearest hospital
LAC/OLIVE VIEW-UCLA MEDICAL CENTER
6.7 mi
6.7 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. La is a mixed practice specialist, with above-average Medicare volume (top 16% in CA), with low-engagement industry engagement in the top 10% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. La experienced with abatacept infusion (orencia)?
Based on Medicare claims data, Dr. La performed 12,450 abatacept infusion (orencia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. La receive payments from pharmaceutical companies?
Yes. Dr. La received a total of $59,789 from 55 companies across 1,734 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. La's costs compare to other rheumatologists in Tujunga?
Dr. La's average Medicare payment per service is $41. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. La) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in Tujunga
Browse rheumatologists in Tujunga ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in CA
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in CA
Which CA rheumatologists receive the most from drug and device companies.
By company
AbbVie, Inc. Payments to Doctors
See all physicians who received payments from AbbVie, Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Horizon Therapeutics plc Payments to Doctors
See all physicians who received payments from Horizon Therapeutics plc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology